The stock will trade on the upcoming ALTITUDE-AD Phase 2 readout in late 2026, not on quarterly financials. Traders should monitor for any data leaks or abstract publications ahead of the readout. The cash runway into early 2027 provides a limited buffer, and a negative trial result could raise financing risk.
Price Chart
Executive Summary
Acumen Pharmaceuticals reported Q2 2026 EPS of -$0.45, missing the consensus estimate of -$0.41 by 11%. As a pre-revenue clinical-stage biotech, the focus remains on the upcoming Phase 2 ALTITUDE-AD topline results for sabirnetug in late 2026, which is the primary binary catalyst. Cash burn continues, with $110.2M in cash expected to fund operations into early 2027, but the cash runway is tightening relative to the prior quarter.
Key Financial Metrics
Key Facts
- Reported Q2 2026 net loss of $32.7M on EPS of -$0.45, missing consensus of -$0.41.
- Cash, cash equivalents and marketable securities totaled $110.2M as of June 30, 2026, down from $128.4M as of March 31, 2026.
- Topline results from the Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer's disease are expected in late 2026.
- Nominated two Enhanced Brain Delivery (EBD) candidates, ACU301 and ACU401, with an IND filing targeted for mid-2027.
- R&D expenses decreased to $27.8M from $37.1M YoY, primarily due to lower manufacturing and CRO costs for the ALTITUDE-AD trial.
Financial Impact
Net loss of $32.7M for Q2 2026, with cash burn of $24.1M in operating cash flow for Q1 2026 (Q2 cash flow not separately stated). Cash runway extended into early 2027.
Risk Factors
- Phase 2 ALTITUDE-AD trial failure would be a major negative catalyst, potentially wiping out most of the company's value.
- Cash runway only extends into early 2027, creating financing risk if the trial is delayed or requires additional studies.
- Competition from approved anti-amyloid therapies like Leqembi and Kisunla could limit commercial potential even if sabirnetug succeeds.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-055940 |
| Document: acumen_ncxcorporatexdeck.htm | 0001628280-26-055940 |
| Document: abos-20260812.htm | 0001628280-26-055940 |
| Document: 0001628280-26-055940-index-headers.html | 0001628280-26-055940 |
| Document: 0001628280-26-055940-index.html | 0001628280-26-055940 |
| Document: 0001628280-26-055940.txt | 0001628280-26-055940 |
| 8-K Data (Synthetic) | 0001628280-26-055940 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-3 | $2.27 | awaiting T+20 | — | $2.27 (+0.01%) |
Oct 26, 2026 today | 8-K | $2.07 | awaiting T+20 | — | $2.27 (+9.71%) |
Oct 26, 2026 today | Press Release | $2.05 | awaiting T+20 | — | $2.27 (+10.73%) |
Oct 22, 2026 4d ago | Press Release | $2.06 | awaiting T+20 | — | $2.27 (+10.19%) |
Oct 19, 2026 7d ago | Press Release | $2.02 | awaiting T+20 | — | $2.27 (+12.66%) |
Sep 16, 2026 5w ago | 8-K | $2.61 $1.82 | ▼ −30.46% | ▼ −33.64% | $2.27 (−13.03%) |
Aug 12, 2026 10w ago | Institutional Cluster | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.27 (−9.56%) |
Aug 12, 2026 10w ago | 8-K | $2.51 $2.86 | ▲ +13.94% | ▲ +15.84% | $2.27 (−9.56%) |
Aug 12, 2026 10w ago | Press Release | $2.51 $2.86 | ▼ −13.94% | ▼ −15.84% | $2.27 (+9.56%) |
Jun 17, 2026 18w ago | Insider Cluster | $2.26 $2.17 | ▼ −3.98% | ▼ −4.52% | $2.27 (+0.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers